New hope for hard-to-treat gut cancers: targeted combo tested
Disease control
Completed
This study tested a new drug called ERAS-007 combined with other cancer treatments in 101 people with advanced colorectal or pancreatic cancer that had spread. The main goals were to find the safest dose and check for side effects. The approach targets a specific cell pathway (MA…
Phase: PHASE1, PHASE2 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 04, 2026 16:18 UTC